High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

J.L. Kuiper, D.A.M. Heideman, E. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1399-401
Number of pages3
JournalEuropean Journal of Cancer
Issue number7
Publication statusPublished - May 2014

Cite this